Company profile
X4 PHARMACEUTICALS, INC
NASDAQ:XFORBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| XOLREMDI | approved | $1.5MQ4 2024 | 12 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03005327 | phase2 | completed | 2016-12-01 | 2022-06-16 | X4 Pharmaceuticals | A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome |
| NCT02680782 | phase1 | terminated | 2016-01-12 | 2016-02-28 | X4 Pharmaceuticals | A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers |
| NCT04274738 | phase1 | completed | 2020-04-30 | 2022-10-31 | X4 Pharmaceuticals | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 |
| NCT04154488 | phase1_2 | completed | 2021-10-16 | 2024-08-27 | X4 Pharmaceuticals | A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders |
| NCT06056297 | phase3 | recruiting | 2024-06-06 | 2027-09-01 | X4 Pharmaceuticals | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 218709 | 2024-04-26 | NDA | X4 PHARMACEUTICALS INC | |||||
Loading… | ||||||||